Quick Answer
Cyclerion Therapeutics, Inc. reported Stockholders Equity of $9.09 million for the year ending 2025.
- Cyclerion Therapeutics, Inc. showed an increase of +2.7% in Stockholders Equity from 2024 to 2025.
- This data is from Cyclerion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$4.75 million | Q2 2018: -$8.61 million | Q3 2018: -$8.12 million | Q1 2019: -$7.75 million | Q2 2019: $141.19 million | Q3 2019: $119.20 million | Q1 2020: $81.54 million | Q2 2020: $66.10 million | Q3 2020: $75.35 million | Q1 2021: $48.43 million | Q2 2021: $65.22 million | Q3 2021: $56.39 million | Q1 2022: $37.03 million | Q2 2022: $25.36 million | Q3 2022: $16.52 million | Q1 2023: $3.93 million | Q2 2023: $5.15 million | Q3 2023: $12.87 million | Q1 2024: $9.92 million | Q2 2024: $8.78 million | Q3 2024: $8.20 million | Q1 2025: $8.78 million | Q2 2025: $8.57 million | Q3 2025: $9.54 million.
- Over the full 9 years of available data (2017 to 2025), Cyclerion Therapeutics, Inc.'s Stockholders Equity has grown by 206.0%.
- Historical annual values: Fiscal year 2025: $9.09 million | Fiscal year 2024: $8.85 million | Fiscal year 2023: $11.29 million | Fiscal year 2022: $10.45 million | Fiscal year 2021: $48.25 million | Fiscal year 2020: $59.49 million | Fiscal year 2019: $97.73 million | Fiscal year 2018: -$10.45 million | Fiscal year 2017: -$8.57 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: